- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28 result(s) found for: Ideal Body Weight.
Displaying page 1 of 2.
EudraCT Number: 2009-016857-16 | Sponsor Protocol Number: AGO/2009/010 | Start Date*: 2010-06-09 |
Sponsor Name:University Hospital Ghent | ||
Full Title: Dose finding study for effective reversal of a moderate rocuronium-induced neuromuscular block with sugammadex in morbidly obese patients | ||
Medical condition: Morbidly obese patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016998-15 | Sponsor Protocol Number: TeriTrama_1.0 | Start Date*: 2009-12-03 | ||||||||||||||||
Sponsor Name:University of Turku | ||||||||||||||||||
Full Title: Effect of terbinafine and itraconazole on the pharmacokinetics and pharmacodynamics of oral tramadol: A three-phase randomized balanced cross-over study in healthy volunteers | ||||||||||||||||||
Medical condition: Acute postoperative pain and chronic pain syndromes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020617-82 | Sponsor Protocol Number: TicloTrama_1.0 | Start Date*: 2010-08-12 | ||||||||||||||||
Sponsor Name:University of Turku | ||||||||||||||||||
Full Title: Effect of itraconazole and ticlopidine on the pharmacokinetics and pharmacodynamics of oral tramadol: A three-phase randomized balanced cross-over study in healthy volunteers | ||||||||||||||||||
Medical condition: Acute postoperative pain and chronic pain syndromes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003715-94 | Sponsor Protocol Number: IDEAL | Start Date*: 2020-12-17 |
Sponsor Name:Institute for Clinical and Experimental Medicine | ||
Full Title: INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi | ||
Medical condition: Type 2 diabetes mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) HU (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003005-27 | Sponsor Protocol Number: 2007-987 | Start Date*: 2007-09-27 | ||||||||||||||||
Sponsor Name:Dept. of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital Rigshospitalet | ||||||||||||||||||
Full Title: Pharmacodynamic trial on rocuronium in obese patients | ||||||||||||||||||
Medical condition: Laparoscopic gastric banding or gastric bypass in propofol/remifentanil anaesthesia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006440-55 | Sponsor Protocol Number: Amino Acid 01/2007 | Start Date*: 2007-08-27 | |||||||||||
Sponsor Name:University Childrin's Hospital | |||||||||||||
Full Title: Effect on metabolic acidosis due to hyperammonemia of high versus low intake of amino acid in VLBW infants. | |||||||||||||
Medical condition: At birth, a VLBW infant is abruptly disconnected from the ideal source of parenteral nutrition - the placenta. If the goal of post-natal nutrition in the VLBW infant is to mimic in utero nutrition.... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000537-69 | Sponsor Protocol Number: PROP2% | Start Date*: 2015-09-21 |
Sponsor Name:Universitair Ziekenhuis Brussel | ||
Full Title: Real time monitoring of blood propofol concentration | ||
Medical condition: - General anaesthesia - Pharmacokinetics and Pharmacodynamics of Propofol - Inflammatory parameters - Elective thyroid, oncologic breast,ENT or cervical arthrodesis surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003259-20 | Sponsor Protocol Number: VenlaTrama_1.0 | Start Date*: 2011-09-08 | ||||||||||||||||
Sponsor Name:University of Turku | ||||||||||||||||||
Full Title: Effect of duloxetine and venlafaxine on the pharmacokinetics and pharmacodynamics of oral tramadol: A three-phase randomized balanced cross-over study in healthy volunteers | ||||||||||||||||||
Medical condition: Acute postoperative pain and chronic pain syndromes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000179-34 | Sponsor Protocol Number: P53 | Start Date*: 2013-08-28 |
Sponsor Name:Maastricht University | ||
Full Title: More creative on cocaine? | ||
Medical condition: It is not really a medical condition that is being investigated. The present research proposal has been designed 1) to assess creativity during cocaine intoxication, and 2) to define the potentia... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004728-11 | Sponsor Protocol Number: MR/EUM202 | Start Date*: 2005-03-25 |
Sponsor Name:Avera Pharmaceuticals Inc. | ||
Full Title: A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate The Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patien... | ||
Medical condition: Adjunct to anesthesia to facilitate tracheal intubation (non-depolarizing neuromuscular blocking agent) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002135-26 | Sponsor Protocol Number: 4PH/2011/002 | Start Date*: 2012-02-16 | |||||||||||
Sponsor Name:AESCULAPIUS FARMACEUTICI S.R.L. | |||||||||||||
Full Title: Efficacy and Safety of Acyclovir 5 Lipstick (Contra) in Treatment of Skin Infections Provoked by Herpes Simplex. A Randomised, Double-blind, Placebo Controlled, Parallel Group Study. | |||||||||||||
Medical condition: History of recurrent herpes labialis with at least 3 recurrences during the past 12 months and typically (>50% of episodes) associated with prodromal symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000188-33 | Sponsor Protocol Number: MK-8616-146 | Start Date*: 2017-10-27 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or ... | |||||||||||||
Medical condition: Reversal of neuromuscular blockade | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019831-36 | Sponsor Protocol Number: CACS-2010 | Start Date*: 2011-04-21 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI | |||||||||||||
Full Title: A phase III randomized trial comparing two regimens for treatment of cancer anorexia / cachexia syndrome(CACS). | |||||||||||||
Medical condition: Cancer anorexia / cachexia syndrome in patients with advanced tumors of different sites | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002871-32 | Sponsor Protocol Number: Rifabupre | Start Date*: 2012-08-28 |
Sponsor Name:Turku University hospital | ||
Full Title: Effects of rifampicin on the pharmacokinetics and pharmacodynamics of sublingual and intravenous buprenorphine: A four-phase cross-over study in healthy subjects. | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004905-17 | Sponsor Protocol Number: PIR112487 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-020953-14 | Sponsor Protocol Number: PosaBupreversion1.0 | Start Date*: 2010-08-12 |
Sponsor Name:Derartment of Anaesthesiology and Intensive Care, Turku University Hospital | ||
Full Title: Effects of posaconazole and voriconazole on the pharmacokinetics and pharmacodynamics of sublingual buprenorphine: A three-phase double-blind cross-over study in healthy subjects. | ||
Medical condition: - healty volunteer subjects - The study is aimed to examine the possible interactions of low-dose sublingual buprenorphine with posaconazole and voriconazole. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001191-30 | Sponsor Protocol Number: RDEA594-401 | Start Date*: 2017-09-27 | |||||||||||
Sponsor Name:Ironwood Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared W... | |||||||||||||
Medical condition: Gout and moderate renal impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023986-23 | Sponsor Protocol Number: LF-0802 | Start Date*: 2011-05-27 | |||||||||||
Sponsor Name:Agennix Incorporated | |||||||||||||
Full Title: OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis | |||||||||||||
Medical condition: Severe Sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005537-35 | Sponsor Protocol Number: E5564-G000-301 | Start Date*: 2006-08-30 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis | |||||||||||||
Medical condition: Severe Sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) AT (Completed) CZ (Completed) ES (Completed) DE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001061-83 | Sponsor Protocol Number: 2215-CL-0304 | Start Date*: 2017-07-13 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | |||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with... | |||||||||||||
Medical condition: FMS-like tyrosine kinase 3 (FLT3) / internal tandem duplication (ITD) (FLT3/ITD) acute myeloid leukemia (AML) in first morphologic complete remission (CR1) that has been treated with allogeneic hem... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Ongoing) PL (Completed) DK (Completed) FR (Ongoing) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.